Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: Towards evidence-based approaches

British Journal of Haematology

Volumn 150, Issue 5, 2010, Pages 515-528

  Coppola, Antonio ^a   Di Minno, Matteo N D ^a   Santagostino, Elena ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

haemophilia A; immune tolerance induction; inhibitors; prognostic factors; treatment

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; PROTEIN A; RITUXIMAB; SEPHAROSE; ALLOANTIBODY;

ARTHROPATHY; BLEEDING; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; EVIDENCE BASED PRACTICE; GENE MUTATION; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROVOCATION TEST; REVIEW; ANTAGONISTS AND INHIBITORS; BLOOD; EVIDENCE BASED MEDICINE; IMMUNOLOGY; MALE; PATIENT SELECTION;

EVIDENCE-BASED MEDICINE; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; ISOANTIBODIES; MALE; PATIENT SELECTION; PROGNOSIS;

EID: 77955793307     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08263.x     Document Type: Review

References (92)

1. Aledort, L.M., Kroner, B. Mariani, G. (2000) Hemophilia treatment. Immune tolerance induction: treatment duration analysis and economic considerations. Haematologica, 85 (Suppl. 10 83 85.
2. Astermark, J., Oldenburg, J., Pavlova, A., Berntorp, E. Lefvert, A.K. the MIBS Study Group 2006a) Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood, 107, 3167 3172.
3. Astermark, J., Oldenburg, J., Carlson, J., Pavlova, A., Kavakli, K., Berntorp, E. Lefvert, A.K. (2006b) Polymorphisms in the TNFA gene and risk of inhibitor development in patients with hemophilia A. Blood, 108, 3739 3745.
4. Astermark, J., Morado, M., Rocino, A., van den Berg, H.M., von Depka, M., Gringeri, A., Mantovani, L., Garrido, R.P., Schiavoni, M., Villar, A. Windyga, J. on behalf of the EHTSB 2006c) Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia, 12, 363 371.
5. Astermark, J., Wang, X., Oldenburg, J., Berntorp, E. Lefvert, A.K., MIBS Study Group 2007) Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. Journal of Thrombosis and Haemostasis, 5, 263 265.
6. Auerswald, G., Spranger, T. Brackmann, H.H. (2003) The role of plasma-derived factor VIII/von Willebrand concentrates in the treatment of hemophilia A patients. Haematologica, 88 (Suppl. 9 21 25.
7. Auerswald, G., von Depka Prondzinski, M., Ehlken, B., Kreuz, W., Kurnik, K., Lenk, H., Scharrer, I., Scramm, W. Zimmermann, R. (2004) Treatment patterns and cost-of-illness of severe haemophilia in patients with inhibitors in Germany. Haemophilia, 10, 499 508.
8. Barnes, C., Rivard, G.E., Poon, M.-C., Teitel, J., Pai, M., Kern, M., Blanchette, V.S. Carcao, M. (2006) Canadian multiinstitutional survey of immune tolerance therapy (ITT) - experience with the use of recombinant factor VIII for ITT. Haemophilia, 12, 1 6.
9. Batlle, J., Lopez, M.F., Brackmann, H.H., Gaillard, S., Goudemand, J., Humbert, J., De Moerloose, P., Maass, E., Mauz-Körholz, C., Sultan, Y. Stieltjes, N. (1999) Induction of immune tolerance with recombinant factor VIII in haemophilia A patients with inhibitors. Haemophilia, 5, 431 435.
10. Behrmann, M., Pasi, J., Saint-Remy, J.M., Kotitsche, R. Kloft, M. (2002) Von Willebrand modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model. Thrombosis and Haemostasis, 88, 221 229.
11. Berntorp, E. (2001) Immune tolerance induction: recombinant vs. human-derived product. Haemophilia, 7, 109 113.
12. Berntorp, E., Shapiro, A., Astermark, J., Blanchette, V.S., Collins, P.W., DiMichele, D., Escuriola, C., Hay, C.R., Hoots, W.K., Leissinger, C.A., Negrier, C., Oldenburg, J., Peerlinck, K., Reding, M.T. Hart, C. (2006) Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia, 12 (Suppl. 6 1 7.
13. Brackmann, H.H. Gormsen, J. (1977) Massive factor VIII infusion in haemophiliac with factor VIII inhibitor, high responder. Lancet, 310, 933.
14. Brackmann, H.H., Oldenburg, J. Schwaab, R. (1996) Immune tolerance for the treatment of factor VIII inhibitors - twenty years''Bonn protocol'. Vox Sanguinis, 70 (Suppl. 1 30 35.
15. Carcao, M. Lambert, T. (2010) Prophylaxis in haemophilia with inhibitors: update from international experience. Haemophilia, 16 (Suppl. 2 16 23.
16. Carcao, M., St Louis, J., Poon, M.-C., Grunebaum, E., Lacroix, S., Stain, A.M., Blanchette, V.S. Rivard, G.E. on behalf of the Inhibitor Subcommittee of the Association of Hemophilia Clinic Directors of Canada 2006) Rituximab for congenital hemophiliacs with inhibitors: a Canadian experience. Haemophilia, 12, 7 18.
17. Collins, P.W., Mathias, M., Hanley, J., Keeling, D., Keenan, R., Laffan, M., Perry, D. Liesner, R. United Kingdom Haemophilia Centre Doctors' Organisation 2009) Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort. Journal of Thrombosis and Haemostasis, 7, 787 794.
18. Colowick, A.B., Bohn, R.L., Avorn, J. Ewenstein, B.M. (2000) Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood, 96, 1698 1702.
19. Coppola, A., Margaglione, M., Santagostino, E., Rocino, A., Grandone, E., Mannucci, P.M. Di Minno, G. for the AICE PROFIT Study Group 2009) Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of patients with severe hemophilia A and high-responding inhibitors. Journal of Thrombosis and Haemostasis, 7, 1809 1815.
20. Coppola, A., Santoro, C., Tagliaferri, A., Franchini, M. Di Minno, G. (2010) Understanding inhibitor development in haemophilia A: towards clinical prediction and prevention strategies. Haemophilia, 16 (Suppl. 1 13 19.
21. Di Minno, M.N.D., Di Minno, G., Di Capua, M., Cerbone, A.M. Coppola, A. (2010) Cost of care of haemophilia with inhibitors. Haemophilia, 16, e190 e201.
22. van Dijk, K., van der Bom, J.G., Bax, K.N., van der Zee, D.C. van den Berg, H.M. (2004) Use of implantable venous access devices in children with severe hemophilia: benefits and burden. Haematologica, 89, 189 194.
23. DiMichele, D. (2009) The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy. Haemophilia, 15, 320 328.
24. DiMichele, D. Hay, C.R. (2006) The international immune tolerance study: a multicenter prospective randomized trial in progress. Journal of Thrombosis and Haemostasis, 4, 2271 2273.
25. DiMichele, D.M. Kroner, B.L. (2002) The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thrombosis and Haemostasis, 87, 52 57.
26. DiMichele, D.M., Hoots, W.K., Pipe, S.W., Rivard, G.E. Santagostino, E. (2007) International workshop on immune tolerance induction: consensus recommendations. Haemophilia, 13 (Suppl. 1 1 22.
27. Escuriola-Ettingshausen, C. Kreuz, W. (2005) Role of von Willebrand factor in immune tolerance induction. Blood Coagulation & Fibrinolysis, 16 (Suppl. 1 S27 S31.
28. Ewenstein, B.M., Valentino, L.A., Journeycake, J.M., Tarantino, M.D., Shapiro, A.D., Blanchette, V.S., Hoots, W.K., Buchanan, G.R., Manco-Johnson, M.J., Rivard, G.E., Miller, K.L., Geraghty, S., Maahs, J.A., Stuart, R., Dunham, T. Navickis, R.J. (2004) Consensus recommendations for use of central venous access devices in haemophilia. Haemophilia, 10, 629 648.
29. Ewing, N.P., Sanders, N.L., Dietrich, S.L. Kasper, C.K. (1988) Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors. Journal of the American Medical Association, 259, 65 68.
30. Franchini, M. Mannucci, P.M. (2010) Comorbidities and quality of life in elderly persons with haemophilia. British Journal of Haematology, 148, 522 533.
31. Franchini, M., Mengoli, C., Lippi, G., Targher, G., Montagnana, M., Salvagno, G.L., Zaffanello, M. Cruciani, M. (2008) Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patients' analysis. Haemophilia, 14, 903 912.
32. Freiburghaus, C., Berntorp, E., Ekman, M., Gunnarsson, M., Kjellberg, B. Nilsson, I.M. (1999) Tolerance induction using the Malmo treatment model 1982-1995. Haemophilia, 5, 32 39.
33. Goodeve, A.C. Peake, I.R. (2003) The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development. Seminars in Thrombosis & Hemostasis, 29, 23 30.
34. Gouw, S.C., van der Bom, J.G. van den Berg, H.M. for the CANAL Study Group 2007) Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood, 109, 4648 4654.
35. Grenninger, D.A., Saint-Remy, J.M., Jacquemin, M., Benhida, A. DiMichele, D.M. (2008) The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile. Haemophilia, 14, 295 302.
36. Gringeri, A. (2007) VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study. Haemophilia, 13 (Suppl. 5 73 77.
37. Gringeri, A. Mannucci, P.M. for the Italian Association of Haemophilia Centres 2005) Italian guidelines for diagnosis and treatment of patients with haemophilia and inhibitors. Haemophilia, 11, 611 619.
38. Gringeri, A., Mantovani, L.G., Scalone, L. Mannucci, P.M. (2003) Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood, 102, 2358 2363.
39. Gringeri, A., Musso, R., Mazzucconi, M.G., Piseddu, G., Schiavoni, M., Pignoloni, P. Mannucci, P.M. for the RITS-FITNHES Study Group 2007) Immune tolerance induction with a high-purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia, 13, 373 379.
40. Gruppo, R.A., Valdez, L.P. Stout, R.D. (1992) Induction of immune tolerance in patients with hemophilia A and inhibitors. American Journal of Pediatric Hematology and Oncology, 14, 82 87.
41. Hay, C.R., Baglin, T.P., Collins, P.W., Hill, F.G. Keeling, D.M. (2006) The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors Organization (UKHCDO). British Journal of Haematology, 133, 591 605.
42. Hay, C.R.M., Goldberg, I., Foulkes, M. DiMichele, D.M. on behalf of the International Immune Tolerance Study Group 2010) International prospective randomized immune tolerance (ITI) study: interim analysis of therapeutic efficacy and safety. Haemophilia, 16, 405.
43. Haya, S., Lopez, M.F., Aznar, J.A. Batlle, J. (2001) Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry. Haemophilia, 7, 154 159.
44. Hodge, G. Han, P. (2001) Effect of intermediate-purity factor VIII (FVIII) concentrate on lymphocyte proliferation and apoptosis: transforming growth factor-beta is a significant immunomodulatory component of FVIII. British Journal of Haematology, 115, 376 381.
45. Knight, C. (2005) Health economics of treating haemophilia A with inhibitors. Haemophilia, 11 (Suppl. 1 11 17.
46. Konkle, B.A., Ebbesen, L.S., Erhardtsen, E., Bianco, R.P., Lissitchkov, T., Rusen, L. Serban, M.A. (2007) Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. Journal of Thrombosis and Haemostasis, 5, 1904 1913.
47. Kreuz, W., Ehrenforth, S., Funk, M., Auerswald, G., Mentzer, D., Joseph-Steiner, J., Beeg, T., Klarman, D., Scharrer, I. Kornhuber, B. (1995) Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up. Haemophilia, 1, 24 32.
48. Kreuz, W., Escuriola-Ettingshausen, C., Auerswald, G., Heidemann, P., Kemkes-Matthes, B. Schneppenheim, R. (2001) Immune tolerance induction (ITI) in haemophilia A with inhibitors: the choice of concentrate affecting success. Haematologica, 86 (Suppl. 4 16 20.
49. Kroner, B.L. (1999) Comparison of the international immune tolerance registry and the North American immune tolerance registry. Vox Sanguinis, 77 (Suppl. 1 33 37.
50. Kucharski, W., Scharf, R. Nowak, T. (1996) Immune tolerance induction in haemophiliacs with inhibitor to FVIII: high- or low-dose programme. Haemophilia, 2, 224 228.
51. Kurth, M.A., DiMichele, D., Sexauer, C., Sanders, J.M., Torres, M., Zappa, S.C., Ragni, M. Leonard, N. (2008) Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors. Haemophilia, 14, 50 55.
52. van Leeuwen, E.F., MauserBunschoten, E.P., van Dijken, P.J., Kok, A.J., Sjamsoedin-Visser, E.J.M. Sixma, J.J. (1986) Disappearance of factor VIII:C antibodies in patients with haemophilia A upon frequent administration of factor VIII in intermediate or low dose. British Journal of Haematology, 64, 291 297.
53. Lenk, H. (2000) The German registry of immune tolerance treatment in hemophilia - 1999 update. Haematologica, 85, 45 47.
54. Ljung, R. (2007) The risk associated with indwelling catheters in children with haemophilia. British Journal of Haematology, 138, 580 586.
55. Manco-Johnson, M.J., Abshire, T.C., Shapiro, A.D., Riske, B., Hacker, M.R., Kilcoyne, R., Ingram, J.D., Manco-Johnson, M.L., Funk, S., Jacobson, L., Valentino, L.A., Hoots, W.K., Buchanan, G.R., DiMichele, D., Recht, M., Brown, D., Leissinger, C., Bleak, S., Cohen, A., Mathew, P., Matsunaga, A., Medeiros, D., Nugent, D., Thomas, G.A., Thompson, A.A., McRedmond, K., Soucie, J.M., Austin, H. Evatt, B.L. (2007) Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. New England Journal of Medicine, 357, 535 544.
56. Mancuso, M.E., Mannucci, P.M., Sartori, A., Agliardi, A. Santagostino, E. (2008) Feasibility of prophylaxis and immune tolerance induction regimens in haemophilic children using fully implantable central venous catheters. British Journal of Haematology, 141, 689 695.
57. Mancuso, M.E., Berardinelli, L., Beretta, C., Raiteri, M., Pozzoli, E. Santagostino, E. (2009) Improved treatment feasibility in children with hemophilia using arteriovenous fistulae: the results after seven years of follow-up. Haematologica, 94, 687 692.
58. Mannucci, P.M. (2008) Back to the future: a recent history of haemophilia treatment. Haemophilia, 14 (Suppl. 3 10 18.
59. Mariani, G. Kroner, B. for the Immune Tolerance Study Group 2001) Immune tolerance in hemophilia with inhibitors: predictors of success. Haematologica, 86, 1186 1193. (Pubitemid 33063865)
60. Mariani, G., Ghirardini, A. Bellocco, R. (1994) Immune tolerance in hemophilia - principal results from the International Registry. Report of the factor VIII and IX Subcommittee. Thrombosis and Haemostasis, 72, 155 158.
61. Mathias, M., Khair, K., Hann, I. Liesner, R. (2004) Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia. British Journal of Haematology, 125, 366 368.
62. Mauser-Bunschoten, E.P., Nieuwenhuis, H.K., Roosendaal, G. van den Berg, H.M. (1995) Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood, 86, 983 988.
63. McCarthy, W.J., Valentino, L.A., Bonilla, A.S., Goncharova, I., Taylor, A., Pooley, T.A. Jacobs, C.E. (2007) Arteriovenous fistula for long-term venous access for boys with hemophilia. Journal of Vascular Surgery, 45, 986 991.
64. Mehta, R., Parameswaran, R. Shapiro, A.D. (2006) An overview of the history, clinical practice concerns, comparative studies and strategies to optimize therapy of bypassing agents. Haemophilia, 12 (Suppl. 6 54 61.
65. Morfini, M., Haya, S., Tagariello, G., Pollmann, H., Quintana, M., Siegmund, B., Stieltjes, N., Dolan, G. Tusell, J. (2007a) European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia, 13, 606 612.
66. Morfini, M., Auerswald, G., Kobelt, R.A., Rivolta, G.F., Rodriguez-Martorell, J., Scaraggi, F.A., Altisent, C., Blatny, J., Borel-Derlon, A. Rossi, V. (2007b) Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres. Haemophilia, 13, 502 507.
67. Nilsson, I.M., Berntorp, E. Zettervall, O. (1988) Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. New England Journal of Medicine, 318, 947 950.
68. Oldenburg, J., Schwaab, R. Brackmann, H.H. (1999) Induction of immune tolerance in haemophilia A inhibitor patients by the "Bonn Protocol": predictive parameter for therapy duration and outcome. Vox Sanguinis, 77 (Suppl. 1 49 54.
69. Orsini, F., Rotschild, C., Beurrier, P., Faradji, A., Goudemand, J. Polack, B. (2005) Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors. Haematologica, 90, 1288 1290.
70. Paisley, S., Wight, J., Currie, E. Knight, J. (2003) The management of inhibitors in haemophilia A: introduction and systematic review of current practice. Haemophilia, 9, 405 417.
71. Pavlova, A., Delev, D., Lacroix-Desmazes, S., Schwaab, R., Mende, M., Fimmers, R., Astermark, J. Oldenburg, J. (2009) Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A. Journal of Thrombosis and Haemostasis, 7, 2006 2015.
72. Peerlinck, K. Hermans, C. (2006) Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy. Haemophilia, 12, 579 590.
73. Peyvandi, F., Jayandharan, G., Chandi, M., Srivastava, A., Nakaya, S.M., Johnson, M.J., Thompson, A.R., Goodeve, A., Garagiola, I., Lavoretano, S., Menegatti, M., Palla, R., Spreafico, M., Tagliabue, L., Asselta, R., Duga, S. Mannucci, P.M. (2006) Genetic diagnosis of haemophilia and other inherited bleeding disorders. Haemophilia, 12 (Suppl. 3 82 89.
74. Reipert, B.M., van den Helden, P.M.W., Schwarz, H.-P. Hausl, C. (2006) Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors. British Journal of Haematology, 136, 12 25.
75. Rocino, A., Papa, M.L., Salerno, E., Capasso, F., Miraglia, E. de Biasi, R. (2001) Immune tolerance induction in haemophilia A patients with high-responding inhibitors to factor VIII: experience at a single institution. Haemophilia, 7, 33 38.
76. Rocino, A., Santagostino, E., Mancuso, M.E. Mannucci, P.M. (2006) Immune tolerance induction with recombinant factor VIII in hemophilia A patients with high responding inhibitors. Haematologica, 91, 558 561.
77. Rothschild, C., Laurian, Y., Satre, E.P., Borel Derlon, A., Chambost, H., Moreau, P., Goudemand, J., Parquet, A., Peynet, J., Vicariot, M., Beurrier, P., Claeyssens, S., Durin, A., Faradji, A., Fressinaud, E., Gaillard, S., Guérin, V., Guérois, C., Pernod, G., Pouzol, P., Schved, J.F. Gazengel, C. (1998) French previously untreated patients with severe hemophilia A after exposure to recombinant Factor VIII: incidence of inhibitor and evaluation of immune tolerance. Thrombosis and Haemostasis, 80, 779 783.
78. Salviato, R., Bellini, D., Radossi, P., Sartori, R., Pierobon, F., Zanotto, D., Zanon, E., Castaman, G., Gandini, G. Tagariello, G. (2007) F8 gene mutation profile and ITT response in a cohort of Italian haemophilia A patients with inhibitors. Haemophilia, 13, 361 372.
79. Santagostino, E., Mancuso, M.E., Rocino, A., Mancuso, G., Mazzucconi, M.G., Tagliaferri, A., Messina, M. Mannucci, P.M. (2005) Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. British Journal of Haematology, 130, 422 427.
80. Santagostino, E., Auerswald, G., Jimenez-Yuste, V., Ljung, R., Morfini, M., Rocino, A. Young, G. (2010) European Initiative to prevent joint damage in haemophilia children with inhibitors (ENJOIH) - a prospective study. Haemophilia, 16, 407.
81. Scalone, L., Mantovani, L.G., Mannucci, P.M. Gringeri, A. (2006) Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia, 12, 154 162.
82. Schwaab, R., Brackmann, H.H., Meyer, C., Seehafer, J., Kirchgesser, M., Haack, A., Olek, K., Tuddenham, E.G. Oldenburg, J. (1995) Haemophilia A: mutation type determines the risk of inhibitor formation. Thrombosis and Haemostasis, 74, 1402 1406.
83. Smith, M.P., Spence, K.J., Waters, E.L., Beresford-Webb, R., Mitchell, M.J., Cuttler, J., Alhaq, A., Brown, S.A. Savidge, G.F. (1999) Immune tolerance therapy for haemophilia A patients with acquired factor VIII alloantibodies: comprehensive analysis of experience at a single institution. Thrombosis and Haemostasis, 81, 35 38.
84. Suzuki, T., Arai, M., Amano, K., Kagawa, K. Fukutake, K. (1996) Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor. Thrombosis and Haemostasis, 76, 749 754.
85. UK Haemophilia Centre Doctors' Organization (2004) The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. Journal of Thrombosis and Haemostasis, 2, 1047 1054.
86. Unuvar, A., Warrier, I. Lusher, J.M. (2000) Immune tolerance induction in the treatment of pediatric haemophilia A. Haemophilia, 6, 150 157.
87. Valentino, L.A. (2009) Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors. Haemophilia, 16, 263 271.
88. Valentino, L.A., Ewenstein, B., Navickis, R.J. Wilkes, M.M. (2004) Central venous access devices in haemophilia. Haemophilia, 10, 134 146.
89. ®) for immune tolerance induction in patients with haemophilia A. Haemophilia, 15, 727 732.
90. Viel, K.R., Ameri, A., Abshire, T.C., Iyer, R.V., Watts, R.G., Lutcher, C., Channell, C., Cole, S.A., Fernstrom, K.M., Nakaya, S., Kasper, C.K., Thompson, A.R., Almasy, L. Howard, T.E. (2009) Inhibitors of factor VIII in black patients with hemophilia. New England Journal of Medicine, 360, 1618 1627.
91. Waters, B. Lillicrap, D. (2009) The molecular mechanisms of immunomodulation and tolerance induction to factor VIII. Journal of Thrombosis and Haemostasis, 7, 1446 1456.
92. Wight, J., Paisley, S. Knight, C. (2003) Immune tolerance induction in patients with haemophilia A with inhibitors. A systematic review. Haemophilia, 9, 436 463. (Pubitemid 36874392)